Systematic review of ixabepilone for treating metastatic breast cancer

Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results.

(2017) H. S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)

(2015) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

(2013) John W. Smith et al.   BREAST CANCER RESEARCH AND TREATMENT

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

(2013) Linda T. Vahdat et al.   BREAST CANCER RESEARCH AND TREATMENT

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

(2013) Hope S. Rugo et al.   BREAST CANCER RESEARCH AND TREATMENT

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial

(2013) George Fountzilas et al.   PLoS One

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

(2013) Linda T. Vahdat et al.   Journal of Geriatric Oncology

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2010) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients

(2010) Ellen B. Kossoff et al.   MEDICAL ONCOLOGY

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

(2009) Stacy Moulder et al.   BREAST CANCER RESEARCH AND TREATMENT

Pharmacodynamics of Tubulin and Tubulin-Binding Agents: Extending Their Potential Beyond Taxanes

(2008) Eleni Andreopoulou et al.   Clinical Breast Cancer

Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models

(2008) F. Y.F. Lee et al.   CLINICAL CANCER RESEARCH